Schizophrenia Research
Volume 73, Issue 2 , Pages 379-381 , 1 March 2005

Serum glutamic acid decarboxylase 65 antibody levels in people with schizophrenia and their families

  • Fiona Gaughran

      Affiliations

    • Institute of Psychiatry, De Crespigny Park, Camberwell, London SE5 8AF, UK
    • Corresponding Author InformationCorresponding author. Fourth Floor, Ladywell Unit, South London and Maudsley Trust, University Hospital, Lewisham, London, SE13 6LW, UK. Tel.: +44 208 333 3000x8024; fax: +44 208 333 3402.
    • ,
  • Louisa Chrisman

      Affiliations

    • Medical student, Kings College, London, UK
    • ,
  • Oliver D. Howes

      Affiliations

    • Institute of Psychiatry, De Crespigny Park, Camberwell, London SE5 8AF, UK
    • ,
  • Angela Vincent

      Affiliations

    • Neurosciences Group, Institute of Molecular Medicine, John Radcliffe Hospital, Oxford OX3 9DS, UK

Received 31 March 2004

References 

  1. Atkinson MA, Bowman MA, Campbell L, Darrow BL, Kaufman DL, Maclaren NK. Cellular immunity to a determinant common to glutamate decarboxylase and coxsackie virus in insulin-dependent diabetes. Journal of Clinical Investigation. 1994;94(5):1713
  2. Benes FM, Todtenkopt M, Logiotatos P, Williams M. Glutamate decarboxylase 65 immunoreactive terminals in cingulate and prefrontal cortices of schizophrenia and bipolar brain. Journal of Clinical Neuroanatomy. 2000;20:259–269
  3. Cainelli F, Manzaroli D, Renzini C, Casali F, Concia E, Vento S. Coxsackie B virus-induced autoimmunity to GAD does not lead to type 1 diabetes. Diabetes Care. 2000;23(7):1021–1022
  4. Cannon M, Jones PB, Murray RM. Obstetric complications and Schizophrenia: historical and meta-analytic review. American Journal of Psychiatry. 2002;159:180–192
  5. Deutsch SI, Rosse RB, Schwartz BL, Mastropaolo J. A revised excitotoxic hypothesis of schizophrenia: therapeutic implications. Clinical Neuropharmacology. 2001;24(1):43–49
  6. Gaughran F, O'Neill E, Cole M, Collins K, Daly RJ, Shanahan F. Increased soluble interleukin 2 receptor levels in schizophrenia. Schizophrenia Research. 1998;29:263–267
  7. Gaughran F, O'Neill E, Sham P, Daly RJ, Shanahan F. Soluble interleukin 2 receptor levels in families of people with schizophrenia. Schizophrenia Research. 2002;56(3):235–239
  8. Petersen JS, Dyrberg T, Damm P, Kuhl C, Molsted-Pedersen L, Buschard K. GAD65 autoantibodies in women with gestational or insulin dependent diabetes mellitus diagnosed during pregnancy. Diabetologia. 1996;39(11):1329–1333
  9. Rantakallio P, Jones P, Moring J, Von Wendt L. Association between central nervous system infections during childhood and adult onset schizophrenia and other psychoses: a 28-year follow-up. International Journal of Epidemiology. 1997;26(4):837–843
  10. Wright P, Sham PC, Gilvarry CM, Jones PB, Cannon M, Sharma T, et al. Autoimmune diseases in the pedigrees of schizophrenic and control subjects. Schizophrenia Research. 1996;20:261–267

PII: S0920-9964(04)00169-0

doi: 10.1016/j.schres.2004.05.004

Schizophrenia Research
Volume 73, Issue 2 , Pages 379-381 , 1 March 2005

Article Tools

* Image Usage & Resolution